About our Formula

Unveiling Our Signature Formula

Central to our mission is the development of a groundbreaking formula—our BPC 157+PEA 500 blend. This unique fusion combines the targeted recovery support of BPC 157 with the wellness-promoting properties of PEA 500, creating a powerful blend aimed at nurturing comprehensive well-being.

The Ultimate Synergy for Wellness

Our BPC 157+PEA 500 formula is designed to deliver a dual impact—enhanced recovery support intertwined with wellness enhancement. This unique synergy integrates the recovery potential of BPC 157 with the wellness support system of PEA 500, offering a transformative formula with the potential to elevate recovery and promote overall vitality.

Elevating Recovery, Amplifying Well-Being

The main advantage of our BPC 157+PEA 500 blend lies in its ability to offer amplified recovery support while promoting an overall sense of well-being. Users of our signature blend have reported experiencing enhanced recovery potential and an uplifted sense of vitality, capturing the essence of transformative well-being woven into every capsule.

Our Dedication to Quality and Transparency

Our commitment to quality, purity, and safety is intrinsic to every batch of our BPC 157+PEA 500 formula. Rigorous testing and quality assurance measures ensure that you receive a product aligned with our unwavering commitment to well-being. Transparency, integrity, and your ultimate well-being are at the heart of our product offerings.

Embrace Well-Being with VitalBPC157

We invite you to experience the transformative potential of our BPC 157+PEA 500 blend. If you seek to elevate recovery, promote vitality, and embark on a journey to enhanced well-being, our signature blend is poised to be your trusted companion. Thank you for choosing VitalBPC157 as your ally in the pursuit of vitality.

References : 

BPC 157 :

  • Staresinic M, Japjec M, Vranes H, Prtoric A, Zizek H, Krezic I, Gojkovic S, Smoday IM, Oroz K, Staresinic E, Dretar V, Yago H, Milavic M, Sikiric S, Lovric E, Batelja Vuletic L, Simeon P, Dobric I, Strbe S, Kokot A, Vlainic J, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022; 10(12):3221. https://doi.org/10.3390/biomedicines10123221
  • Seiwerth, Sven et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” Current pharmaceutical design vol. 24,18 (2018): 1972-1989. doi:10.2174/1381612824666180712110447
  • Gwyer, Daniel et al. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell and tissue research vol. 377,2 (2019): 153-159. doi:10.1007/s00441-019-03016-8
  • Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010
  • Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. doi:10.2174/1570159x13666160502153022
  •  Seiwerth, S., Sikiric, P., Grabarevic, Z., Zoricic, I., Hanzevacki, M., Ljubanovic, D., … Kolega, Z. (1997). BPC 157’s effect on Healing. Journal of Physiology Paris91(3–5), 173–178. https://doi.org/10.1016/S0928-4257(97)89480-6

    Palmitoylethanolamide (PEA):

    • Clayton, Paul et al. “Palmitoylethanolamide: A Natural Compound for Health Management.” International journal of molecular sciences vol. 22,10 5305. 18 May. 2021, doi:10.3390/ijms22105305
    • Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111/bcp.13020. Epub 2016 Jun 29. PMID: 27220803; PMCID: PMC5094513.
    • Paladini, Antonella et al. “Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis.” Pain physician vol. 19,2 (2016): 11-24.
    • Brugnatelli V, Turco F, Freo U, Zanette G. Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment. Front Neurosci. 2020 Apr 21;14:371. doi: 10.3389/fnins.2020.00371. PMID: 32372912; PMCID: PMC7186328.